INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $174,000 | -73.6% | 14,100 | -66.6% | 0.01% | -77.3% |
Q3 2021 | $660,000 | +1550.0% | 42,260 | +185.5% | 0.02% | +2100.0% |
Q2 2021 | $40,000 | -59.2% | 14,800 | -86.3% | 0.00% | -66.7% |
Q4 2020 | $98,000 | -76.6% | 108,300 | -11.4% | 0.00% | -85.7% |
Q3 2020 | $418,000 | -83.0% | 122,300 | -87.5% | 0.02% | -84.4% |
Q2 2020 | $2,457,000 | +7578.1% | 981,427 | +7508.0% | 0.14% | +6650.0% |
Q1 2020 | $32,000 | -99.7% | 12,900 | -99.6% | 0.00% | -99.7% |
Q4 2019 | $12,193,000 | +1561.2% | 3,196,600 | +84.7% | 0.67% | +1032.2% |
Q3 2019 | $734,000 | +280.3% | 1,731,100 | +746.1% | 0.06% | +293.3% |
Q2 2019 | $193,000 | – | 204,600 | +888.4% | 0.02% | – |
Q4 2018 | $0 | -100.0% | 20,700 | -68.4% | 0.00% | -100.0% |
Q3 2017 | $338,000 | +11166.7% | 65,566 | +111.5% | 0.02% | – |
Q2 2017 | $3,000 | -94.2% | 31,000 | -2.8% | 0.00% | -100.0% |
Q1 2017 | $52,000 | -77.4% | 31,900 | -35.9% | 0.00% | -62.5% |
Q3 2016 | $230,000 | – | 49,800 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |